A study of oral microbiome in anti-cyclic citrullinated peptide (anti-CCP) positive at-risk individuals without synovitis (CCP+at risk) shows dysbiotic subgingival microbiomes and increased abundance of P. gingivalis compared with controls.
JAMA Internal Medicine reports an analysis of COVID-19 clinical trials showing that critically ill patients with COVID-19 treated with systemic corticosteroids have an overall lower mortality rate.
Dr. John Cush RheumNow
6 years ago
European collaborative study of eosinophilic granulomatosis with polyangiitis (EGPA) Rx w/ RTX, mepolizumab or omalizumab (OMA). MEP > RTX > OMA. Mepolizumab was highly effective in GC‐dependent asthma. https://t.co/fi8pjnJO03
Dr. John Cush RheumNow
6 years ago
Swedish population study of psoriasis pts Rx w/ secukinumab (848) or ustekinumab (1107) showed slightly more respiratory infx & UTI (HR 1.22), w/ no difference in hospital treated severe respiratory, UTI (HR 0.96) or candidiasis (HR 1.80) https://t.co/yIRubED6VX
k dao KDAO2011
6 years ago
"Prednisone >30 mg/day for > 4 weeks, patients should be on PJP prophylaxis."
Image shows when to start/stop PJP prophylaxis
Dr. Kevin Winthrop on Risks/Prevention of OI @UTSWRheum Grand Rounds @rheumnow https://t.co/nXuWYRxbgy
The Nobel Assembly at Karolinska Institutet has awarded the 2020 Nobel Prize in Physiology or Medicine jointly to Harvey J. Alter, Michael Houghton and Charles M. Rice for the discovery of Hepatitis C virus. These three scientists made a decisive contribution to the fight against blood-borne hepatitis C, a major global health problem that causes cirrhosis and liver cancer in people around the world.
Dr. John Cush RheumNow
6 years ago
Utilization study of 1031 tofacitinib vs 17,803 biologic DMARD Rx-patients shows 14% higher discontinuations w/ TOFA (HR 1.14), but pts who switched to tofacitinib from a bDMARD had longer persistence than pts switched to another bDMARD (HR 0.90) https://t.co/5cqloTTbjb
Dr. John Cush RheumNow
6 years ago
Hellenic reigstry of 385 RA pts on DMARDs finds that, compared to remission or LDAS - those in persistent moderated disease activity had 50-80% more serious adverse events. https://t.co/3JA3VaMxeO
Dr. John Cush RheumNow
6 years ago
Among 406 axial SpA patients in the DESIR Cohort smoking was associated with MRI‐SI joint after 5 years of axial SpA patients and only in blue‐collar job or low education levels; suggesting a possible role for mechanical stress axial SpA. https://t.co/fcDjesdF8K
Dr. John Cush RheumNow
6 years ago
Danish comparison of 15K RA, 301K Diabetes adn 75K gen population; RA assoc w/ increased risk of CHF (HR 1.51), MI (HR 1.58), stroke (HR 1.22) vs gen. population; but RA had 20-40% lower CHF/MI/CVA than diabetes pts (who had highest 10 yr mortality). https://t.co/R20EUPAlML
Dr. John Cush RheumNow
6 years ago
RheumNow Podcast is up! COVID effects on Rheum; drug approvals, Difficult RA, SLE complement & remission. Watch it here> https://t.co/490T6k1ytk or listen to the podcast on iTunes> https://t.co/FHJv01AAbC OR on souncloud>
https://t.co/dAJ0827c3B
Dr. John Cush RheumNow
6 years ago
Predictors of Remission in SLE? metanalysis of 17270 SLE pts; 42-88% achieved remission x 1 yr, & 21-70% for 5 yrs. Remission assoc w/ older age , lower Dz activity & No major organ involvement; positive serologies negatively associated w/ remission https://t.co/2aoGgnY6kw
Dr. John Cush RheumNow
6 years ago
FDA Issues Final Guidance for Labeling Recommendations on Breast Implants, after review of data & commentary. Implants have been assoc w/anaplastic large cell lymphoma & breast implant illness (BII) w/ fatigue, “brain fog,” rash, myalgia, arthralgia. . https://t.co/HozSCRx4JH
